Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy

Table 1

Summary of bone marrow, FISH, and cytogenetic findings.

Timing	Blast (%)	FISH		Karyotype
		CEP ×3; (normal: 0.0–2.0%)	CEP7 ×1; (normal: 0.0–6.0%)
At diagnosis	82.4	65% [325/500]	23.4% [117/500]	51,XY,+6,+8,inv(9)(p12q13)c,+11,+13,+19[]/52,idem,+Y[]
After induction; (IDA-AraC)	3.2	0.6% [3/500]	73.4% [367/500]	45,XY,-7,inv(9)(p12q13)c[]/46,XY,inv(9)(p12q13)c[]
After consolidation; (Mit-VP16-AraC)	5.4	1.2% [6/500]	65.8% [329/500]	45,XY,-7,inv(9)(p12q13)c[]/46,XY,inv(9)(p12q13)c[]
After Azacytidine	4.4	0.6% [3/500]	84.4% [422/500]	n/a
After HSCT	0.2	0.8% [4/500]	0.6% [3/500]	46,XY[]
Relapse	45.4	0.2% [1/500]	56.4% [282/500]	n/a

IDA: Idamycin; AraC: cytarabine; Mit: mitoxantrone; VP16: etoposide; HSCT: Hematopoietic Stem Cell Transplantation.
Centromere probe for chromosome 7. Centromere probe for chromosome 8.